Legal Representation
Attorney
Tiffany D. Gehrke
USPTO Deadlines
Next Deadline
2131 days remaining
Section 8 Declaration Due (Principal Register) (Based on registration date 20251028)
Due Date
October 28, 2031
Grace Period Ends
April 28, 2032
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
46 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Oct 28, 2025 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED | Loading... |
| Oct 28, 2025 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Oct 9, 2025 | SUNA | E | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | Loading... |
| Oct 9, 2025 | CNPR | P | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | Loading... |
| Sep 16, 2025 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Sep 16, 2025 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Sep 10, 2025 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Jun 12, 2025 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Jun 12, 2025 | GNRT | O | NON-FINAL ACTION E-MAILED | Loading... |
| Jun 12, 2025 | CNRT | W | SU - NON-FINAL ACTION - WRITTEN | Loading... |
| May 15, 2025 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| May 15, 2025 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| May 15, 2025 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Apr 30, 2025 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Feb 3, 2025 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Feb 3, 2025 | GNRT | O | NON-FINAL ACTION E-MAILED | Loading... |
| Feb 3, 2025 | CNRT | W | SU - NON-FINAL ACTION - WRITTEN | Loading... |
| Jan 13, 2025 | SUPC | I | STATEMENT OF USE PROCESSING COMPLETE | Loading... |
| Oct 28, 2024 | IUAF | S | USE AMENDMENT FILED | Loading... |
| Jan 11, 2025 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
| Oct 28, 2024 | EISU | I | TEAS STATEMENT OF USE RECEIVED | Loading... |
| Jun 18, 2024 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Apr 23, 2024 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Apr 23, 2024 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Apr 3, 2024 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Mar 16, 2024 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Feb 27, 2024 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Feb 27, 2024 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Feb 27, 2024 | ERFR | I | TEAS REQUEST FOR RECONSIDERATION RECEIVED | Loading... |
| Dec 18, 2023 | XELG | O | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | Loading... |
| Dec 18, 2023 | XELR | I | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | Loading... |
| Oct 2, 2023 | GNFN | O | NOTIFICATION OF FINAL REFUSAL EMAILED | Loading... |
| Oct 2, 2023 | GNFR | O | FINAL REFUSAL E-MAILED | Loading... |
| Oct 2, 2023 | CNFR | R | FINAL REFUSAL WRITTEN | Loading... |
| Aug 11, 2023 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Aug 10, 2023 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Aug 10, 2023 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Jul 3, 2023 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| May 11, 2023 | XELG | O | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | Loading... |
| May 11, 2023 | XELR | I | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | Loading... |
| Feb 14, 2023 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Feb 14, 2023 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Feb 14, 2023 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Feb 7, 2023 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Jun 30, 2022 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Jun 20, 2022 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Cells for medical or clinical use in the field of in vivo gene editing therapy for the treatment of cardiovascular diseases; pharmaceutical and biopharmaceutical agents for the treatment of cardiovascular disease in the field of in vivo gene editing therapy; gene therapy products, namely, gene transfer, regulation, modulation and delivery pharmaceuticals for the treatment of cardiovascular disease in the field of in vivo gene editing therapy
First Use Anywhere:
Nov 17, 2023
First Use in Commerce:
Nov 17, 2023
Class 042
Gene editing, namely, medical and scientific research for the treatment of genetic diseases and disorders in the field of in vivo gene editing therapy; gene editing, namely, pharmaceutical research and development in the field of in vivo gene editing therapy
First Use Anywhere:
Nov 17, 2023
First Use in Commerce:
Nov 17, 2023
Additional Information
Pseudo Mark
CTX THREE ONE ZERO; CTX THREE HUNDRED TEN
Classification
International Classes
005
042